feed,title,long_url,short_url
Benzinga,Sims Limited Included on Global 100 List of the World's Most Sustainable Companies,https://www.benzinga.com/pressreleases/21/01/n19290470/sims-limited-included-on-global-100-list-of-the-worlds-most-sustainable-companies,https://j.mp/365Wj4I
Benzinga,Sims Limited Included on Global 100 List of the World's Most Sustainable Companies,https://www.benzinga.com/pressreleases/21/01/n19290469/sims-limited-included-on-global-100-list-of-the-worlds-most-sustainable-companies,https://j.mp/3sSDhbI
Benzinga,Roche renews partnership with Sysmex to deliver haematology testing solutions,https://www.benzinga.com/pressreleases/21/01/tr19290464/roche-renews-partnership-with-sysmex-to-deliver-haematology-testing-solutions,https://j.mp/2YogR4p
Benzinga,How Florida Healthcare Law Firm is handling the Lab Compliance and Pharmacy Law Remaining a Challenge in COVID-Impacted Florida,https://www.benzinga.com/pressreleases/21/01/n19290459/how-florida-healthcare-law-firm-is-handling-the-lab-compliance-and-pharmacy-law-remaining-a-challe,https://j.mp/3sQ9Gjg
Benzinga,"Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million",https://www.benzinga.com/pressreleases/21/01/g19290457/philips-delivers-q4-sales-of-eur-6-0-billion-with-7-comp-sales-growth-income-from-cont-operations-,https://j.mp/3r1hwVJ
Benzinga,"Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. operations increases to EUR 608 million, Adjusted EBITA margin improves 110 bps to 19.0%, and operating cash flow increases to EUR 1,305 million",https://www.benzinga.com/pressreleases/21/01/tr19290456/philips-delivers-q4-sales-of-eur-6-0-billion-with-7-comp-sales-growth-income-from-cont-operations,https://j.mp/2MkYMBg
Benzinga,Roche's faricimab meets primary endpoint in two global phase III studies and shows potential to extend time between treatments up to 16 weeks for people with neovascular age-related macular degeneration,https://www.benzinga.com/pressreleases/21/01/tr19290455/roches-faricimab-meets-primary-endpoint-in-two-global-phase-iii-studies-and-shows-potential-to-ex,https://j.mp/3oaKTCR
Benzinga,Genentech's Faricimab Meets Primary Endpoint in Two Global Phase III Studies and Shows Potential to Extend Time Between Treatments up to 16 Weeks for People With Neovascular Age-Related Macular Degeneration,https://www.benzinga.com/pressreleases/21/01/b19290458/genentechs-faricimab-meets-primary-endpoint-in-two-global-phase-iii-studies-and-shows-potential-to,https://j.mp/2MiLWng
